Why Wave Life Sciences, Inc.’s (WVE) Stock Is Down 6.10%
As of Monday, November 16, Wave Life Sciences, Inc.’s WVE share price has dipped by 6.10%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Jenna Brashear
Rosalio Madrigal
Tudor Pop
Michael Rose
Cynthia McLaughlin
| Share Statistics | WVE | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $546.3 | $421.0 | 40% |
|
| Shares Out (Mil) | 204.2 | 46.5 | 76% |
|
| Institutional Ownership | 99.4% | 82.0% | 87% |
|
| Float (Mil) | 105.0 | 48.3 | 61% |
|
| Beta | -1.43 | 0.68 | 1% |
|
| Avg Daily Volume (000s) | 2,701 | 348 | 85% |
|
| Price Change (52-week) |
(61.3%) | 52.0% | 15% |
|
| Growth | WVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 16.3% | 6.6% | 75% |
|
| Net Income (5yr) | (6.4%) | (1.6%) | 33% |
|
| EPS (5yr) | 20.5% | 15.1% | 69 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 13.4% | (15.1%) | 71% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 17 | 16 | 18 | |
| Current EPS | ($0.317) | ($1.093) | ($1.191) | |
| Month Ago EPS | ($0.325) | ($1.105) | ($1.167) | |
| # Rev Up | 0 | 1 | 0 | |
| # Rev Down | 3 | 0 | 1 | |
| Three Months Ago EPS | ($0.331) | ($1.109) | ($1.191) | |
| Year/Year Chg | 4.6% | (9.8%) | 2.5% | |
| Financials | WVE | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $71 | $289 | 23% |
|
| Net Income (TTM) (Mil) | ($211) | ($11) | 6% |
|
| EPS (TTM) | ($1.068) | ($0.600) | 20% |
|
| Operating Cash Flow (TTM) (Mil) | ($207) | ($7) | 4% |
|
| Net Cash Flow (TTM) (Mil) | $1 | $1 | 48% |
|
| Long-Term Debt (Q1) (Mil) | $39 | $4 | 37% |
|
| Enterprise Value (Q1) (Mil) | $330 | $331 | 31% |
|
| Valuation | WVE | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.36 | 2.27 | 40% |
|
| P/E | na | 24.1 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | WVE | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (189.6%) | 69.4% | 1% |
|
| Net Margin | (296.9%) | 3.9% | 3% |
|
| ROA | (56.2%) | (23.8%) | 10% |
|
| ROE | (80.0%) | (24.7%) | 11% |
|
| Liabilities to Assets | 20.9% | 32.0% | 13% |
|
| F-Score | 2 | 3 | 7% |
|
Wave Life Sciences, Inc. did not pass any screens on 11/18/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors